Discover 3,005 paid clinical trials in Riverside, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,005
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
for
Healthy Subject, Hematologic and Lymphocytic Disorder,
Location: Los Angeles CA
Sponsor: University of Southern California
Sex: All
Age: 19+
Code: NCT03207854
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
for
Macular Edema
Location: Arcadia CA, Huntington Beach CA, Pasadena CA, Poway CA,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT06962839
Phase 2, Recruiting
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
for
Peripheral T-Cell Lymphoma, Not Otherwise Specified,
Location: Irvine CA, Duarte CA, San Francisco CA, Portland OR,
Sponsor: Corvus Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06561048
Phase 3, Recruiting
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
for
Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
Location: Los Angeles CA, Santa Rosa CA, Laredo TX, Dallas TX,
Sponsor: NGM Biopharmaceuticals, Inc
Sex: All
Age: 18+
Code: NCT07033026
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Dupilumab in the Treatment of Pediatric Alopecia Areata
for
Alopecia Areata
Location: Irvine CA, San Diego CA, Chicago IL, New York NY
Sponsor: Icahn School of Medicine at Mount Sinai
Sex: All
Age: 6 - 17
Code: NCT05866562
Phase 2, Recruiting
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia